Ayaka Yoshikawa

Takatsuki, 5698686, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Real-world comparison of herpes zoster risk among five Janus kinase inhibitors in rheumatoid arthritis: The ANSWER cohort study.

Real-world comparison of herpes zoster risk among five Janus kinase inhibitors in rheumatoid arthritis: The ANSWER cohort study.

Journal: Joint bone spine

Published: March 26, 2026

Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort.

Clinical outcomes of molecular-targeted therapies for rheumatoid arthritis: comparison between orthopaedic surgeons and rheumatologists in the multicenter retrospective ANSWER cohort.

Journal: Clinical rheumatology

Published: February 12, 2026

Mode of action-specific and cause-specific retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in anti-SS-A antibody-positive rheumatoid arthritis: The ANSWER cohort study.

Mode of action-specific and cause-specific retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in anti-SS-A antibody-positive rheumatoid arthritis: The ANSWER cohort study.

Journal: PloS one

Published: December 01, 2025

Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in RA: the ANSWER cohort study.

Baseline neutrophil-to-lymphocyte ratio predicts drug retention of IL-6 inhibitors and JAK inhibitors in RA: the ANSWER cohort study.

Journal: Rheumatology (Oxford, England)

Published: August 01, 2025

Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study.

Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study.

Journal: Rheumatology (Oxford, England)

Published: June 17, 2025

Predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis using machine learning: a deep learning model trained on the KURAMA cohort and externally validated with the ANSWER cohort.

Predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis using machine learning: a deep learning model trained on the KURAMA cohort and externally validated with the ANSWER cohort.

Journal: Arthritis research & therapy

Published: February 03, 2025

Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort study.

Distinct impact of RF and ACPA titre on the effectiveness and persistency of biologics and JAK inhibitors: The ANSWER cohort study.

Journal: Modern rheumatology

Published: January 17, 2025

The Therapeutic Efficacy of Abatacept for Rheumatoid Arthritis-Associated Interstitial Lung Disease: Insights from a 12-Month Trial Using Semi-Quantitative Chest High-Resolution Computed Tomography Imaging.

The Therapeutic Efficacy of Abatacept for Rheumatoid Arthritis-Associated Interstitial Lung Disease: Insights from a 12-Month Trial Using Semi-Quantitative Chest High-Resolution Computed Tomography Imaging.

Journal: Journal of clinical medicine

Published: September 10, 2024

Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.

Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.

Journal: Clinical and experimental medicine

Published: February 27, 2024

Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.

Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.

Journal: Rheumatology (Oxford, England)

Published: January 10, 2024

Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis.

Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis.

Journal: Rheumatology (Oxford, England)

Published: April 16, 2023

Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study.

Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study.

Journal: International journal of molecular sciences

Published: February 28, 2023

Showing 1-12 of 29

Last Updated: 09/26/2026